BCG vaccine - Vakzine Project Management/Serum Institute of India

Drug Profile

BCG vaccine - Vakzine Project Management/Serum Institute of India

Alternative Names: rBCG-delta-ureC-Hly; rBCGdeltaUreCHly; VPM-1002; VPM-1002BC

Latest Information Update: 17 Dec 2015

Price : $50

At a glance

  • Originator Max Planck Institute for Infection Biology
  • Developer Serum Institute of India; Swiss Group for Clinical Cancer Research; Vakzine Projekt Management
  • Class Antituberculars; Tuberculosis vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis
  • Phase I/II Bladder cancer

Most Recent Events

  • 18 Aug 2015 Phase-II development is ongoing for Tuberculosis (In neonates, Prevention) in South Africa
  • 01 Aug 2015 Phase-I/II clinical trials in Bladder cancer (Recurrent) in Switzerland (Intravesicular) (NCT02371447)
  • 01 Jun 2015 Serum Institute of India in collaboration with Vakzine Projekt Management initiates enrolment in a phase II trial for Tuberculosis (In neonates, Prevention) in South Africa (NCT02391415)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top